Mechelen, Belgium; 28 June 2010 – Galapagos NV (Euronext:
GLPG) announced today a €0.35 million capital increase
arising from employee warrant exercises. Galapagos also
announced that it has received transparency notifications
from Apax and Gestion, pursuant to the Belgian transparency
legislation (Belgian Act of 2 May 2007) concerning major
holdings in Belgian listed companies.
Share
capital increase
Since its inception in 1999, Galapagos has used warrant
plans to incentivize personnel and management and have them
share in the success of the company. Following warrant exercises
during the exercise period in June 2010, Galapagos issued
40,160 new ordinary shares on 28 June 2010 for a total capital
increase, including share premium, of €349,831.11,
or an average of €8.71 per new share. No member of
the Board or Executive Committee exercised warrants. Following
today’s capital increase, Galapagos now has a share
capital amounting to €129,233,772.58, with a total
of 23,890,038 ordinary shares outstanding. There are no
other voting securities.
Transparency
information
Following on the announcement of a successful private placement
on 17 June 2010, Galapagos received a transparency notification
on 24 June 2010 that Altamir Amboise SCA, and Apax Partners
SA acting as manager of FCPR Apax France, sold a combined
total of 1,277,366 shares in the Company, reducing their
combined holding to zero shares.
Galapagos
received a transparency notification on 28 June 2010 indicating
that Mr. A. Strating, TWE Beheer, TWE Investment, and Gestion
Deelnemingen V currently hold a combined 1,252,550 shares
(5.25%); this represents an increase from the 1,184,692
shares (5.02%) previously notified by Gestion Deelnemingen
V.
About
Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology
company specialized in the discovery and development of
small molecule and antibody therapies with novel modes-of-action.
The Company is progressing one of the largest pipelines
in biotech, with four clinical and over 50 small molecule
discovery/pre-clinical programs. Through risk/reward-sharing
alliances with GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica,
Merck & Co. and Roche, Galapagos is eligible to receive
up to €3 billion in downstream milestones, plus royalties.
Together with its BioFocus and Argenta service operations,
Galapagos has over 670 employees and operates facilities
in six countries, with global headquarters in Mechelen,
Belgium. More info at: www.glpg.com
CONTACT
Galapagos
NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
Elizabeth
Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com
This release may contain forward-looking statements,
including, without limitation, statements containing the
words “believes,” “anticipates,”
“expects,” “intends,” “plans,”
“seeks,” “estimates,” “may,”
“will,” “could,” “stands to,”
and “continues,” as well as similar expressions.
Such forward-looking statements may involve known and unknown
risks, uncertainties and other factors which might cause
the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial
conditions, performance or achievements expressed or implied
by such forward-looking statements. Given these uncertainties,
the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements
speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any
such forward-looking statements in this document to reflect
any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any
such statement is based, unless required by law or regulation.
